Medinol, a small Israeli stent company, used innovative stent design and manufacturing processes to develop products that propelled its marketing partner, Boston Scientific, to early leadership in what became the biggest cardiovascular device market of the past decade.
Problems resulting in litigation led Medinol to recently terminate the collaboration after six years, leaving the small firm with the choice of going it alone and having to build a worldwide sales and marketing network, or seeking another partner.
The break-up occurs at a pivotal point in the development of coronary stent technology; bare metal stents are apparently about to give way to the next-generation drug-eluting stents (DES), which present perhaps an even larger opportunity than that enjoyed bvy their predecessors. Medinol is skipping over DES and is already working on the next-generation stent/drug therapy.
Because of consolidation, the stent market is now dominated by four major playuers. Yet, Medinol chose to end its alliance with one of the Big Four to join forces with a much smaller player in this space, WL Gore & Associates Inc. Both Medinol and Gore are R&D-driven, and are betting that the rules of the stent game haven't changed: that ultimately in interventional cardiology, the best technology still wins.
by Stephen Levin
To an outside observer, the first ten years of the life of Medinol Ltd. , the Tel Aviv, Israel-based stent company founded in 1992, would truly seem to embody...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.
Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.
As the health care industry undergoes a digital transformation, the integration of AI into Quality and Regulatory Management Systems is proving essential. The challenges for successful AI deployment emphasize the need for robust digital infrastructure, data literacy programs and privacy measures to enhance patient safety and commercial performance.
Almost halfway through 2025, and financing for European biotech could be described as challenging. Market volatility, geopolitical instability and trade barriers all loom large in biotech CEO minds when pitching for funding. In Vivo talked to biotechs and investors to gain a realistic view of the current market for company funding so far this year.
From chemical engineering to cancer innovation, AbbVie's rising oncology leader is advancing next-generation ADCs to tackle difficult-to-treat tumors with a patient-centered approach.
Mini-profiles of five synthetic biology companies and their leaders from SynBioBeta 2025 reveal how AI integration, data-driven platforms and interdisciplinary teams are revolutionizing drug discovery and manufacturing.